Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Priorix was reconstituted using DTaP IPV liquid (component of Pentacel); Priorix was reconstituted using DTaP IPV liquid (component of Pentacel)/Reconstitution with a different diluent; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced wrong solution used in drug reconstitution (Verbatim: Priorix was reconstituted using DTaP IPV liquid (component of Pentacel)) and inappropriate dose of vaccine administered (Verbatim: Priorix was reconstituted using DTaP IPV liquid (component of Pentacel)/Reconstitution with a different diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 01-JUL-2025 The reporter mentioned that Priorix was reconstituted using DTaP-IPV liquid (component of Pentacel) which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered The pharmacist enquired if they have any information on safety and stability when Priorix was reconstituted with anything else other than the provided diluent.